Today, the World Health Organization (“WHO”) prequalified Samsung Bioepis’s breast cancer biosimilar trastuzumab – WHO’s first biosimilar prequalification. Prequalification is “a service provided by WHO to assess the quality, safety and efficacy of those products that address global public health priorities.” The WHO noted that the global average price of…
